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points, showing an AUC = 0.89; p < 0.0005, sensitivity value of
0.807, speciﬁcity of 0.841 and kappa coefﬁcient of agreement
with reference clinical diagnosis of 0.65. The scale also showed
good concurrent validity with LANSS classiﬁcation of subjects;
kappa 0.61; p < 0.0005. CONCLUSION: The Spanish version of
the ID Pain questionnaire is feasible, reliable and appropriated as
a self-administered screening tool for pain with a neuropathic
component.
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OBJECTIVES: This study was designed to capture utility values
for health states related to malignant (MP) and non-malignant
(NMP) severe chronic pain treated with intrathecal (IT) analge-
sia. METHODS: Literature review and in depth interviews with
clinical experts (n = 5) led to the development of health state
descriptions. These were deﬁned using visual analogue scale of
pain intensity (VASPI) ranges 0–40, 41–60, 61–80 and 81–100
for both MP and NMP. Additionally 8 health states representing
common adverse events associated with IT therapy were pro-
duced. A discussion guide based on the dimensions of the EQ-5D
was developed. Health states were piloted with cognitive debrief-
ing with ﬁve members of the UK general public. Time trade off
interviews were administered to the UK general public (n = 102)
to estimate utilities for the health states. A repeated measurement
model on the TTO utilities was estimated to account for intra-
patient correlation in the data. Using the predicted values from
this model, utilities were obtained for all possible VASPI scores.
RESULTS: Participants were generally well matched to the
census proﬁle of England and Wales with some small differences
in mean age, race and education. Utilities ranged from 0.84 for
VASPI 0–40 (for NMP & MP) to -0.15 and -0.20 for VASPI
81–100 (NMP & MP respectively). The values for side effects
(irrespective of the context of chronic pain) were as follows
dizziness (0.40); nausea (0.45); pruritis (0.82); confusional state
(0.41); abnormal gait (0.67); urinary retention (0.69); weight
gain (0.77) and erectile dysfunction (0.69). The results also show
a substantial decline in utility scores related to more severe VASPI
values for non-malignant, and malignant disease. CONCLU-
SION: The study shows a signiﬁcant decrement in utility moving
from less severe to more severe levels of chronic pain. The general
public recognise the very signiﬁcant impact that severe chronic
pain has on HRQL.
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OBJECTIVES: In 1975, Melzack developed the McGill Pain
Questionnaire (MPQ), which is composed of four major parts
and evaluates the quality of pain. Objective: The aim of this
study is to assess the reliability, and validity of the MPQ on a
sample of Turkish general population. METHODS: This study
used the data from a Web-based questionnaire. This has been
administered to 342 participants. RESULTS: The results indicate
that the scale is reliable (r = 0.887). Four factors with Eigen
values over one have been extracted after evaluating the factor
analysis. This has accounted for 62.3% of the variance. Corre-
lations between sensory and evaluative subscales have been low
(r = 0.436, p < 0.01), and the most positive correlation has been
seen between the miscellaneous and sensory (r = 0.656,
p < 0.01), as well as affect subscales (r = 0.601, p < 0.01). Dis-
criminate validity has been evaluated by comparing the patient
and control group’s scores. For miscellaneous (p = 0.002) and
affect (p = 0.006) subscales statistical differences have been
found. The correlations between MPQ (subscales and all scale)
and Visual Analogue Scale point has been calculated with Spear-
man correlation for divergent validity. The correlation between
VAS and Pain Rating Index for the patient group has been
moderate (rho = 0.59, p = 0.000) and low for the control group
(rho = 0.32, p = 0.000). For both groups, most strong correlation
with the Visual Analogue Scale has been seen for the affect and
evaluation subscales of MPQ. CONCLUSION: These results
support the Turkish-MPQ as a reliable and valid measure for
evaluating the quality of pain in the Turkish population. Turkish
MPQ can be used in clinical researches to follow and to evaluate
the patients.
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OBJECTIVES: To evaluate the impact of secondary prophylactic
use (PU) of tacrolimus 0.1% ointment on the quality of life
(QoL), outcomes and costs in comparison to standard use (SU) of
tacrolimus 0.1% ointment in adults with moderate to severe
atopic dermatitis (AD) over one year. METHODS: Data were
generated as part of a multi-centre, pan-European, phase III
clinical trial. Patients were randomised to tacrolimus 0.1% oint-
ment (PU) or vehicle ointment (SU) twice a week, during a
12-month disease control period. In both groups disease exacer-
bations were treated with tacrolimus 0.1% ointment twice daily.
Data on health-related QoL were obtained by using SF-36 ques-
tionnaire. Based on these data, utility values were calculated by
using the algorithm by Brazier et al. 2002. Resource consump-
tion data was derived from a patient questionnaire and pooled to
estimate the costs using German unit cost data. RESULTS:
Seventy-ﬁve patients with PU (57% moderately affected) and 59
patients with SU (59% moderately affected) participated. The
number of disease exacerbations was 2.4 (PU) vs. 5.5 (SU)
(p = 0.0014; moderate AD) and 2.3 (PU) vs. 7.4 (SU)
(p = 0.0002; severe AD). Health-related QoL (utility values) in
PU patients increased from 0.71 to 0.79 (p = 0.0014; moderate
AD) and from 0.66 to 0.75 (p = 0.002; severe AD). In the SU arm
utility values increased from 0.69 to 0.72 (NS; moderate AD) and
from 0.67 to 0.71 (NS; severe AD). In moderately affected
patients mean (SD) total annual cost per patient in the PU arm
was €1525 (1081) vs. €1729 (1209) in the SU arm. Mean (SD)
total annual cost per patient was €2045 (2013) (PU) vs. €2904
(1,510) (SU) in the group of severely affected patients. CON-
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